Immunocine
Immunocine Cancer Center is a personalized cancer-care organization with treatment facilities in Mexico. Founded in 2021, the organization focuses on dendritic-cell-based immunotherapy and individualized treatment programs. Its team includes specialists in oncology, immunology, cell therapy, and clinical care, alongside operational and scientific professionals. Immunocine also provides patient education and consultations to help individuals explore its treatment program and eligibility requireme
Visit WebsiteAbout Immunocine
Immunocine Cancer Center is a privately held cancer-care organization founded in 2021, with treatment facilities in Cancún and Cabo, Mexico. The organization focuses on a personalized approach to cancer care using its dendritic-cell immunotherapy program, alongside patient-specific evaluations and clinical support. Its multidisciplinary team includes oncology and medical specialists, scientific researchers, and cell-therapy professionals. The organization’s leadership includes founder and CEO Dr. Matthew Halpert, Executive Director of Operations Vita Salsman, and Chief Medical Officer Dr. Stephen J. Noga. Immunocine also provides introductory consultations, medical-record reviews, eligibility assessments, and educational resources for prospective patients. Its work brings together scientific research, clinical operations, and patient services in the area of personalized immunotherapy. The treatment’s regulatory status and clinical evidence should be assessed independently when evaluating medical claims or treatment options.